Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the factor
Xa (FXa) inhibitor betrixaban for extended-duration prophylaxis of acute medically ill …

Introduction: Compared to other direct oral anticoagulants, betrixaban has a longer half-life,
smaller peak-trough variance, minimal renal clearance, and minimal hepatic Cytochrome P …

Acutely ill hospitalized medical patients remain at high thromboembolic risk for several
weeks after discharge. Previous trials with extended-duration thromboprophylaxis using …

Prophylaxis for venous thromboembolism (VTE) in hospitalized acutely ill medical patients is
a well‐established practice. Despite the increased use of inpatient prophylaxis, the duration …

Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity
and mortality among acute medically ill patients. More than half of VTE events in this …

Venous thromboembolism (VTE) is a common and preventable cause of morbidity and
mortality in hospitalized patients. Low-molecular-weight heparin, low-dose unfractionated …

Purpose The role of betrixaban in the prevention of venous thromboembolism (VTE) in
acutely medically ill patients and its efficacy and safety profiles are reviewed. Summary …

Venous thromboembolism (VTE) in acute medically ill patients is a leading cause of in-
hospital morbidity and mortality. A majority of these VTE events occur post-discharge, and …

Venous thromboembolism (VTE) is a prevalent yet preventable cause of death, particularly
among hospitalized patients. Studies have shown that the risk of VTE remains high for up to …

Background The APEX trial assessed the safety and efficacy of extended-duration
thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among …